Orion S.A.OECEarnings & Financial Report
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.
What changed in Orion S.A.'s 10-K — 2023 vs 2024
Top changes in Orion S.A.'s 2024 10-K
157 paragraphs added · 87 removed · 72 edited across 8 sections
- Item 7. Management's Discussion & Analysis+63 / −1 · 1 edited
- Item 1A. Risk Factors+39 / −42 · 31 edited
- Item 1. Business+31 / −21 · 19 edited
- Item 7A. Quantitative and Qualitative Disclosures About Market Risk+12 / −12 · 11 edited
- Item 5. Market for Registrant's Common Equity+8 / −7 · 6 edited
Item 1. Business
Business — how the company describes what it does
19 edited+12 added−2 removed74 unchanged
Item 1. Business
Business — how the company describes what it does
Item 1A. Risk Factors
Risk Factors — what could go wrong, per management
31 edited+8 added−11 removed119 unchanged
Item 1A. Risk Factors
Risk Factors — what could go wrong, per management
Item 1C. Cybersecurity
Cybersecurity — threats and controls disclosure
1 edited+0 added−0 removed11 unchanged
Item 1C. Cybersecurity
Cybersecurity — threats and controls disclosure
Item 2. Properties
Properties — owned and leased real estate
2 edited+0 added−0 removed0 unchanged
Item 2. Properties
Properties — owned and leased real estate
Item 3. Legal Proceedings
Legal Proceedings — active lawsuits and investigations
1 edited+0 added−0 removed3 unchanged
Item 3. Legal Proceedings
Legal Proceedings — active lawsuits and investigations
Item 5. Market for Registrant's Common Equity
Market for Common Equity — stock, dividends, buybacks
6 edited+2 added−1 removed6 unchanged
Item 5. Market for Registrant's Common Equity
Market for Common Equity — stock, dividends, buybacks
Item 7. Management's Discussion & Analysis
Management's Discussion & Analysis (MD&A) — revenue / margin commentary
1 edited+62 added−0 removed16 unchanged
Item 7. Management's Discussion & Analysis
Management's Discussion & Analysis (MD&A) — revenue / margin commentary
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Market Risk — interest-rate, FX, commodity exposure
11 edited+1 added−1 removed10 unchanged
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Market Risk — interest-rate, FX, commodity exposure